FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2909527347> ?p ?o ?g. }

• W2909527347 endingPage "1183" @default.
• W2909527347 startingPage "1167" @default.
• W2909527347 abstract "The triple-negative breast cancer subtype (TNBC) is highly aggressive and metastatic and corresponds to 15–20% of diagnosed cases. TNBC treatment is hampered, because these cells usually do not respond to hormonal therapy, and they develop resistance to chemotherapeutic drugs. On the other hand, the severe side effects of cisplatin represent an obstacle for its clinical use. Ruthenium (Ru)-based complexes have emerged as promising antitumor and antimetastatic substitutes for cisplatin. In this study, we demonstrated the effects of a Ru/biphosphine complex, containing gallic acid (GA) as a ligand, [Ru(GA)(dppe)2]PF6, hereafter called Ru(GA), on a TNBC cell line, and compared them to the effects in a nontumor breast cell line. Ru(GA) complex presented selective cytotoxicity against TNBC over nontumor cells, inhibited its migration and invasion, and induced apoptosis. These effects were associated with the increased amount of transferrin receptors (TfR) on tumor cells, compared to nontumor ones. Silencing of TfR decreased Ru(GA) effects on TNBC cells, demonstrating that these receptors were at least partially responsible for Ru(GA) delivery into tumor cells. The Ru(GA) compound must be further studied in different in vivo assays in order to investigate its antitumor properties and its toxicity in complex biological systems." @default.
• W2909527347 created "2019-01-25" @default.
• W2909527347 creator A5028670417 @default.
• W2909527347 creator A5040246880 @default.
• W2909527347 creator A5047958895 @default.
• W2909527347 creator A5048282178 @default.
• W2909527347 creator A5067943824 @default.
• W2909527347 creator A5078876836 @default.
• W2909527347 creator A5080362746 @default.
• W2909527347 creator A5089767410 @default.
• W2909527347 date "2019-01-11" @default.
• W2909527347 modified "2023-10-16" @default.
• W2909527347 title "Transport of the Ruthenium Complex [Ru(GA)(dppe)₂]PF₆ into Triple-Negative Breast Cancer Cells Is Facilitated by Transferrin Receptors" @default.
• W2909527347 cites W1965909855 @default.
• W2909527347 cites W1975232939 @default.
• W2909527347 cites W1990722725 @default.
• W2909527347 cites W1991041500 @default.
• W2909527347 cites W1996888759 @default.
• W2909527347 cites W1997054883 @default.
• W2909527347 cites W2014914212 @default.
• W2909527347 cites W2016475658 @default.
• W2909527347 cites W2018052049 @default.
• W2909527347 cites W2027437657 @default.
• W2909527347 cites W2029442922 @default.
• W2909527347 cites W2033278321 @default.
• W2909527347 cites W2034947652 @default.
• W2909527347 cites W2036786349 @default.
• W2909527347 cites W2040184556 @default.
• W2909527347 cites W2041489148 @default.
• W2909527347 cites W2051730223 @default.
• W2909527347 cites W2054114673 @default.
• W2909527347 cites W2055889127 @default.
• W2909527347 cites W2063148361 @default.
• W2909527347 cites W2069758683 @default.
• W2909527347 cites W2073325679 @default.
• W2909527347 cites W2073725745 @default.
• W2909527347 cites W2075651342 @default.
• W2909527347 cites W2075705506 @default.
• W2909527347 cites W2079495420 @default.
• W2909527347 cites W2080503518 @default.
• W2909527347 cites W2080633639 @default.
• W2909527347 cites W2084112970 @default.
• W2909527347 cites W2088256235 @default.
• W2909527347 cites W2089782169 @default.
• W2909527347 cites W2090111996 @default.
• W2909527347 cites W2093436200 @default.
• W2909527347 cites W2095685494 @default.
• W2909527347 cites W2097768016 @default.
• W2909527347 cites W2103279761 @default.
• W2909527347 cites W2105224075 @default.
• W2909527347 cites W2107277218 @default.
• W2909527347 cites W2109511270 @default.
• W2909527347 cites W2114918609 @default.
• W2909527347 cites W2128914100 @default.
• W2909527347 cites W2130177169 @default.
• W2909527347 cites W2132834292 @default.
• W2909527347 cites W2132928559 @default.
• W2909527347 cites W2135924562 @default.
• W2909527347 cites W2136263397 @default.
• W2909527347 cites W2158840134 @default.
• W2909527347 cites W2159834035 @default.
• W2909527347 cites W2199871211 @default.
• W2909527347 cites W2202334915 @default.
• W2909527347 cites W2331531468 @default.
• W2909527347 cites W2510528245 @default.
• W2909527347 cites W2511087567 @default.
• W2909527347 cites W2585453304 @default.
• W2909527347 cites W2597497008 @default.
• W2909527347 cites W2606415475 @default.
• W2909527347 cites W2740215864 @default.
• W2909527347 cites W2740782577 @default.
• W2909527347 cites W2950662762 @default.
• W2909527347 cites W4211092410 @default.
• W2909527347 cites W4231881929 @default.
• W2909527347 cites W602212531 @default.
• W2909527347 cites W966381494 @default.
• W2909527347 doi "https://doi.org/10.1021/acs.molpharmaceut.8b01154" @default.
• W2909527347 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30633527" @default.
• W2909527347 hasPublicationYear "2019" @default.
• W2909527347 type Work @default.
• W2909527347 sameAs 2909527347 @default.
• W2909527347 citedByCount "33" @default.
• W2909527347 countsByYear W29095273472019 @default.
• W2909527347 countsByYear W29095273472020 @default.
• W2909527347 countsByYear W29095273472021 @default.
• W2909527347 countsByYear W29095273472022 @default.
• W2909527347 countsByYear W29095273472023 @default.
• W2909527347 crossrefType "journal-article" @default.
• W2909527347 hasAuthorship W2909527347A5028670417 @default.
• W2909527347 hasAuthorship W2909527347A5040246880 @default.
• W2909527347 hasAuthorship W2909527347A5047958895 @default.
• W2909527347 hasAuthorship W2909527347A5048282178 @default.
• W2909527347 hasAuthorship W2909527347A5067943824 @default.
• W2909527347 hasAuthorship W2909527347A5078876836 @default.
• W2909527347 hasAuthorship W2909527347A5080362746 @default.
• W2909527347 hasAuthorship W2909527347A5089767410 @default.
• W2909527347 hasConcept C121608353 @default.
• W2909527347 hasConcept C126322002 @default.

• next